Palvella Therapeutics (PVLA) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Palvella Therapeutics (PVLA) has outperformed Xeris Biopharma (XERS) over the past year, gaining 75.5% versus a gain of 24.3%. Over five years, XERS leads with a +409.5% price change compared with -63.6% for PVLA. Palvella Therapeutics is the larger company by market cap ($1.97 billion vs $1.90 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PVLA | XERS |
|---|---|---|
| Share price | $136.57 | $10.44 |
| Market cap | $1.97B | $1.90B |
| 1-day change | +3.98% | +2.45% |
| YTD return | +25.48% | +29.81% |
| 1-year return | +75.47% | +24.27% |
| 5-year return | -63.60% | +409.50% |
| Forward P/E | — | 28.22 |
| EPS (TTM) | $-4.85 | $-0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $291.85M |
| Revenue growth (YoY) | — | +43.72% |
| Net income (latest FY) | $-41.72M | $554.00K |
| Gross margin | — | 85.41% |
| Operating margin | — | 8.53% |
| Net margin | — | 0.19% |
| 52-week high | $161.38 | $11.33 |
| 52-week low | $65.93 | $5.25 |
| Distance from 52-week high | -15.38% | -7.86% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +68.81% | +23.18% |
| Average volume | 211.36K | 2.17M |
| Shares outstanding | 14.41M | 182.32M |
| Employees | 29 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PVLA has outperformed XERS by 51.2 percentage points over the past year.
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
PVLA vs XERS FAQ
Which is bigger, Palvella Therapeutics or Xeris Biopharma?
Palvella Therapeutics (PVLA) is larger, with a market capitalization of $1.97B compared with $1.90B for Xeris Biopharma (XERS).
Which stock has performed better over the past year, PVLA or XERS?
PVLA returned +75.47% over the past 12 months, compared with +24.27% for XERS (price return, excluding dividends). Past performance does not predict future results.
Are Palvella Therapeutics and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.